A transgenic mouse expressing a dominant-negative JNK (dnJNK) under the control of a P2 promotor, enabling adipocyte-specific expression of dnJNK, displayed decreased adipose tissue inflammation and circulating cytokines, as well as reduced early atherosclerosis staining [83]. Here, MAPK8 is linked to atherosclerosis.